Latest Insider Transactions at Mannkind Corp (MNKD)
This section provides a real-time view of insider transactions for Mannkind Corp (MNKD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MANNKIND CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MANNKIND CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2022
|
Alejandro Galindo EVP Endocrine Business Unit |
BUY
Open market or private purchase
|
Direct |
2,334
+0.43%
|
$7,002
$3.17 P/Share
|
|
Jan 31
2022
|
Steven B. Binder EVP Special Projects |
BUY
Open market or private purchase
|
Direct |
711
+0.13%
|
$2,133
$3.17 P/Share
|
|
Aug 27
2021
|
Steven B. Binder EVP Special Projects |
SELL
Payment of exercise price or tax liability
|
Direct |
14,177
-2.59%
|
$56,708
$4.91 P/Share
|
|
Aug 27
2021
|
Michael Castagna Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,358
-2.3%
|
$141,432
$4.91 P/Share
|
|
Aug 27
2021
|
Stuart A Tross Chief People & Workpl Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,177
-2.23%
|
$56,708
$4.91 P/Share
|
|
Aug 27
2021
|
Joseph Kocinsky Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,983
-1.74%
|
$39,932
$4.91 P/Share
|
|
Aug 27
2021
|
Alejandro Galindo EVP Endocrine Business Unit |
SELL
Payment of exercise price or tax liability
|
Direct |
9,616
-1.76%
|
$38,464
$4.91 P/Share
|
|
Aug 27
2021
|
David Thomson EVP Genl Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
14,177
-2.5%
|
$56,708
$4.91 P/Share
|
|
Aug 27
2021
|
David Thomson EVP Genl Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
4,100
-0.72%
|
$16,400
$4.64 P/Share
|
|
Jul 30
2021
|
Michael Castagna Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.32%
|
$10,000
$2.99 P/Share
|
|
Jul 30
2021
|
Alejandro Galindo EVP Endocrine Business Unit |
BUY
Open market or private purchase
|
Direct |
5,000
+0.9%
|
$10,000
$2.99 P/Share
|
|
Jul 30
2021
|
Stuart A Tross Chief People & Workpl Officer |
BUY
Open market or private purchase
|
Direct |
4,476
+0.7%
|
$8,952
$2.99 P/Share
|
|
Jul 30
2021
|
Steven B. Binder EVP Special Projects |
BUY
Open market or private purchase
|
Direct |
748
+0.14%
|
$1,496
$2.99 P/Share
|
|
May 18
2021
|
Alejandro Galindo EVP Endocrine Business Unit |
BUY
Grant, award, or other acquisition
|
Direct |
144,000
+12.5%
|
-
|
|
May 18
2021
|
Michael Castagna Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
416,092
+12.77%
|
-
|
|
May 18
2021
|
Steven B. Binder EVP Special Projects |
BUY
Grant, award, or other acquisition
|
Direct |
148,074
+12.74%
|
-
|
|
May 18
2021
|
David Thomson EVP Genl Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
148,412
+12.25%
|
-
|
|
May 18
2021
|
Joseph Kocinsky Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
147,895
+12.17%
|
-
|
|
May 18
2021
|
Stuart A Tross Chief People & Workpl Officer |
BUY
Grant, award, or other acquisition
|
Direct |
147,717
+11.12%
|
-
|
|
Mar 05
2021
|
Michael Castagna Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
3,000
+50.0%
|
$9,000
$3.38 P/Share
|
|
Jan 31
2021
|
Michael Castagna Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.45%
|
$5,000
$1.33 P/Share
|
|
Jan 31
2021
|
Stuart A Tross Chief People & Workpl Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.03%
|
$5,000
$1.33 P/Share
|
|
Jan 31
2021
|
Steven B. Binder EVP Special Projects |
BUY
Open market or private purchase
|
Direct |
1,557
+0.39%
|
$1,557
$1.33 P/Share
|
|
Dec 28
2020
|
Stuart A Tross Chief People & Workpl Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,729
-0.36%
|
$5,187
$3.33 P/Share
|
|
Nov 14
2018
|
Alejandro Galindo EVP Endocrine Business Unit |
BUY
Open market or private purchase
|
Direct |
34,602
+7.99%
|
$69,204
$2.89 P/Share
|